|
業務類別
|
-- |
|
業務概覽
|
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents anapproach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany. |
| 公司地址
| Gottlieb-Daimler-Strabe 2, Mannheim, BW, DEU, 68165 |
| 電話號碼
| +49 621560030 |
| 傳真號碼
| +49 62216743649 |
| 公司網頁
| https://www.affimed.com |
| 員工數量
| 78 |
| Dr. Wolfgang Fischer |
Chief Operating Officer |
-- |
28/03/2024 |
| Dr. Andreas Harstrick, M.D. |
Chief Medical Officer and Interim Chief Executive Officer |
-- |
28/03/2024 |
| Ms. Denise Mueller |
Chief Business Officer; Co-President Affimed Inc. |
-- |
28/03/2024 |
| Mr. Harry Welten |
Consulting Chief Financial Officer |
-- |
28/03/2024 |
|
|
| Dr. Bernhard R.M. Ehmer |
Member of the Supervisory Board |
28/03/2024 |
| Dr. Thomas O. Hecht |
Chairman of the Supervisory Board |
28/03/2024 |
| Dr. Constanze Ulmer-Eilfort |
Member of the Supervisory Board |
28/03/2024 |
| Dr. Annalisa Mary Jenkins, F.R.C.P.,M.B.B.S. |
Member of the Supervisory Board |
28/03/2024 |
| Dr. Mathieu Simon |
Member of the Supervisory Board |
28/03/2024 |
| Ms. Uta Kemmerich-Keil |
Member of the Supervisory Board |
28/03/2024 |
| Dr. Ulrich M. Grau |
Member of the Supervisory Board |
28/03/2024 |
|
|
|
|
